@drmikeisraetel
2 posts audited · 5 claims analysed
Science evidence grade
Based on 5 claims across 2 audits
4
Supported
80%
0
Overstated
0%
1
Misleading
20%
0
No Evidence
0%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @drmikeisraetel claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
80%
4 claims
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
20%
1 claim
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
0%
0 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(2 posts)
“@drmikeisraetel wants to make all drugs over-the-counter without a prescription 😳 We debate this and much more on @thecheckuppodcast”
Claims 2 and 3 are well-supported: GLP-1/GIP therapies demonstrably reduce kidney failure, cardiovascular mortality, and body weight in high-risk populations, and tirzepatide shows robust obesity prevention/reversal in Phase 3 trials. Claim 1 lacks human evidence for direct longevity effects in non-diseased older adults (no registered trials, no published studies). Claim 4 is misleading: tirzepatide is a dual GIP/GLP-1 co-agonist, not a selective GLP-1 agonist—a pharmacologically distinct category whose added GIP activity drives its superior efficacy. The overall framing overstates by conflating disease-specific mortality reduction with general lifespan extension and mischaracterizing tirzepatide's mechanism.
“My NEW BOOK is on preorder now! Top link in my bio! I wrote this book to describe four things: 1.) What you can do with your diet, your training, your cardio, and modern drugs like peptides to get into your best shape possible. 2.) How soon-to-be-released drugs for fat loss and muscle gain will radically transform you even further and how to use them safely and with caution. 3.) What amazing technological advancements in biotech and cosmetics and surgery portend for the next 5 to 15 years in aesthetics. I describe how in the next 15 years, pretty much EVERYONE will be able to live in the body of their dreams. 4.) Why the quest to look better, otherwise known as vanity, is actually a very psychologically healthy thing if approached properly, and how it should be nothing to be ashamed of. If you’re curious, order the book. And YES, I already recorded the audiobook and it’s gonna be pretty awesome!”
The claim that 'peptides can be used to get into one's best shape possible' is supported by current evidence. Multiple Phase 4 and open-label randomized controlled trials are actively investigating GLP-1 receptor agonists (semaglutide, tirzepatide) for improvements in body composition, lean mass, and physical function in humans. While the creator provided no specific citation, the conceptual claim aligns with documented effects of peptide therapeutics on weight management, fat-free mass preservation, and physical performance in clinical populations. Human trial data exists and is actively accumulating; this is not a preclinical-only claim.
Audit another post from @drmikeisraetel
Paste their social post link to add a new audit